anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Medicament comprises at least one insulin and at least one glucagon-like peptide-1 (GLP-1) agonist. The medicament is formulated and/or confectioned in such a manner that it contains the insulin and GLP-1 agonist in a predetermined amount and is administered in an amount with respect to the need of a patient. Independent claims are also included for: (1) a kit comprising the medicament; (2) a combination of Gly(A21)-Arg(B31)-Arg(B32)-human insulin and desPro 3&gt; 6&gt;-exendin-4(1-39)-Lys 6-NH 2 and/or their salts; (3) treating a patient with the medicament or the kit, comprising (a) selecting a dose of at least one insulin, (b) selecting a dose of at least one GLP-1-agonist, (c) selecting a composition from the first, second and optionally the further composition of the medicaments, which contain the dose of (a) and (b) in a concentration, so that the doses of (a) and (b) are present in same volumes and (d) determining and administering an amount, which corresponds to the doses of (a) and (b); and (4) producing the medicament comprising formulating and/or confectioning so that it contains the insulin and the GLP-1 agonist in a predetermined amount and administering in an amount with respect to the need of a patient; and (5) a device comprising the composition or the kit, where the device contains the pharmaceutical composition of the medicament in separate containers and allows the dosing of the pharmaceutical composition independently from one another. ACTIVITY : Antidiabetic; Anorectic. Test details are described but no results given. MECHANISM OF ACTION : Glucagon-like peptide-1 agonist.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a solid preparation containing a lipophilic material having good fluidity and hardly causing oozing out.  &lt;P&gt;SOLUTION: The solid preparation is obtained by forming an emulsion containing the lipophilic material, a water-soluble macromolecular compound and an adsorbent into powder by a spray-dry method. The solid preparation containing the lipophilic material is a stable preparation hardly causing oozing of the lipophilic material even after long-term preservation. The solid preparation has excellent fluidity to facilitate tableting or encapsulation. The cost required for cleaning is reduced because the attachment to a spray dryer is little.  &lt;P&gt;COPYRIGHT: (C)2004,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an endoscope image filing system capable of acquiring an image having an image quality equal to that of an image photographed by a specific model even when the image is photographed by a model different from the specific model.  &lt;P&gt;SOLUTION: A original image file part 308 stores a digital image which is outputted by an electronic scope 302 provided with an imaging device 301 and is equal to a digital image inputted to an image processing circuit 306. A library part 314 stores a plurality of image processing software. A selecting part 315 selects one from among the plurality of image processing software components stored in the library part. An image reproduction part 316 processes the digital image according to the selected image processing software component so that the digital image can be displayed.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
FIELD: medicine, virology. SUBSTANCE: method relates to method of treatment of patients with HIV-infection. Method involves the use of silver nitrate aqueous solution with N,N&#39;-tetramethylthiazine nitrate in the form rectal curative enemas, once per a 24 h, in the dose 0.1-0.2 g for 10 days. In the process of treatment course kidney and liver function is controlled and urinary excretion of tetramethylthiazine is controlled by its color. Control of treatment efficiency is performed by dynamic data of immunological indices and by results of polymerase chain reaction used for detection of viral RNA and DNA. Method ensures to provide elimination of virus from blood and achieve the stable remission of disease. EFFECT: enhanced effectiveness of treatment. 2 cl
PURPOSE: A composition containing Sargassum siliquastrum extract or fraction or sargachromanol G is provided to prevent and treat bone absorption such as osteroporosis. CONSTITUTION: A pharmaceutical composition for preventing and treating bone absorption-associated diseases such as osteroarthritis, osteroporosis, or Paget&#39;s disease contains Sargassum siliquastrum extract as an active ingredient. The Sargassum siliquastrum extract is obtained by isolating Sargassum siliquastrum with water, low alcohol, n-hexane, ethyl acetate, or dichlomethane. The pharmaceutical composition contains sargachromanol G as an active ingredient. The sargachromanol G is derived from Sargassum siliquastrum. A food composition for preventing and treating bone absorption-associated diseases contain the Sargassum siliquastrum extract or sargachlomanol G.
The invention relates to a method for the preparation of efficient antigen-presenting human .gamma..delta. T cells, to the .gamma..delta. T cells prepared by such a method, and to their use in immunotherapy, vaccination, vaccine development and diagnostics. Similar to dendritic cells (DCs) in potency and efficacy, these human .gamma..delta. T cells process antigens and present antigenic peptides to .alpha..beta. T cells and induce antigen-specific responses (proliferation and differentiation) in naïve .alpha..beta.  T cells. .gamma..delta. T cells are easily purified from peripheral blood, acquire &#34;maturation&#34; status (expression of essential adhesion, co-stimulatory and major histocompatibility complex molecules) within 1 day of in vitro culture under stimulation and induce strong primary and secondary T helper cell and cytotoxic T cell responses. The .gamma..delta. T cells may be used in a method of treatment of tumors or chronic or recurrent infectious diseases, in identification of novel tumor or pathogen-derived antigens, and in the diagnosis of the immune competence of a patient.
Pulmonary arterial hypertension (PAH) is a devastatig disease with high mortality. Familial cases of PAH are usually characterized by autosomal dominant transmission with reduced penetrance, and mutations in Bone Morphogenetic Protein receptor type 2 (BMPR2), account for approximately 70% of familial cases, but some familial cases are of unknown genetic etiology. A novel heterozygous missense variant c.608 G&gt;A, G203D in the KCNK3 (potassium channel subfamily K, member 3) gene was identified as a disease causing candidate gene in the family. Five additional heterozygous missense variants were independently identified in 92 unrelated familial PAH and 230 idiopathic PAH patients, genetically independently confirming the results in the first family. All six novel variants were located in highly conserved domains and were predicted to be damaging. Electrophysiological studies of the channel indicated that these missense mutations all result in loss of function, and some mutations were rescued by the phospholipase inhibitor ONO RS-082.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a compound which is excellent in solubility and the like and is suitable for lesion-selective liposome contrast media.  &lt;P&gt;SOLUTION: This compound represented by the general formula (I) [R is a 8 to 30C alkyl or alkenyl group; L is a divalent linkage group; Ch is a group represented by the general formula (II) or (III)]. A chelate compound having the compound. Or a salt of one of them, and the like. The lesions of blood vessels can selectively be imaged by MRI imaging or scintigraphy imaging using a contrast medium containing liposomes containing the compound or the like.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A protein-rich nutritional food product composed of a probiotic and an edible isolated protein. The probiotic component may comprise Lactobacillus, Bacillus, Streptococcus Bifidobacteria, Saccharomyces or Leuconostoc. The isolated protein may comprise whey proteins, whey growth factor extract, glutamine peptide, egg albumen, soy proteins, or caseinates. This nutritional composition can be in the form of a food product, dietary supplement, or medical food which, upon ingestion, will promote a healthy intestinal microenvironment, provide a source of protein, and assist in the elimination of nitrogenous waste products that can build up in concentration in the circulating blood. Increased concentrations of the wastes are known to exert a negative impact on an individual&#39;s physiology and contribute to a decreased sense of well-being and general malaise. Methods for removing nitrogenous waste products from the blood and ameliorating renal failure using the nutritional product of the invention are also provided.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new transparent viscous oil excellent in water hold rate and glossiness, and capable of substituting transparent viscous oil such as hydrogenated polyisobutene of a petroleum synthetic compound and a high polymerization degree silicone oil, based on its properties such as excellent external transparency and moderate viscosity, and to provide cosmetics compounded with the oil.  &lt;P&gt;SOLUTION: The transparent viscous oil of an esterification reaction product of polyglycerol, having 3-20 average polymerization degree calculated from hydroxy value, with a mixed fatty acid comprising an 8-22C branched fatty acid and a 2-10C dibasic acid, and included in following ranges (1) to (3) is provided, and cosmetics compounded with the oil are used. (1) The molar ratio of the 8-22C branched fatty acid to the 2-10C dibasic acid is from 2.0 to 5.0. (2) The molar ratio of 2-10C dibasic acid to l mole 3-20C polyglycerol of 3-20 average polymerization degree calculated from hydroxy value is from 0.5 to 2.0. And (3) number of hydroxy remaining in the reaction products is ≤0.4×(n+2). (n is the average polymerization degree of polyglycerol, calculated from hydroxy value).  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide means for detecting or treating non-A non-B hepatitis virus.  &lt;P&gt;SOLUTION: The hepatitis C virus (HCV) monoclonal antibody capable of immunologically binding to a polypeptide having a continuous sequence comprising at least eight amino acids. This antibody is a monoclonal antibody binding to a continuous sequence comprising at least eight amino acids. A vaccine composition contains the polypeptide having the continuous sequence comprising at least eight amino acids in a pharmaceutically acceptable vehicle. The continuous sequence comprising at least eight amino acids has at least one site capable of binding to an antibody against HCV.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
Inventors have shown evidence of VEGF accumulation in extracellular Aβ plaques in the post-mortem brain of patients with Alzheimer&#39;s disease (AD) and of the APP/PS1 mouse model of AD. They identified specific binding domains involved in the direct interaction between A0o and VEGF and engineered a peptide that blocks this interaction. The designed peptide binds to Aβ oligomers with high affinity and inhibits the process of Aβ self-aggregation, leading to the blockade of fibrillar aggregation. Furthermore, the peptide prevents soluble Aβ-derived toxins to target synapses in hippocampal neuron cultures and restores long-term potentiation in the hippocampus of the APP/PS1 mouse model of Alzheimer&#39;s disease. Thus, these findings have broad implications for preventing and treating diseases with Aβ neurotoxicity such as Alzheimer&#39;s disease. Accordingly, the invention relates to a peptide comprising the amino acid sequence KRKKSRYKSWSVYVG (SEQ ID NO: 1).
A system and method of generating an enhanced Lund and Browder chart and total body surface area burn score is described herein. In some embodiments, a plurality of images is obtained from of a patient using a camera system. The images may be taken by aligning the patient&#39;s body with pose templates presented on a display of the camera system. The non-skin portions of the images may be removed, and skin analysis performed on the skin portion to determine burn location, coverage, and depth. Further, landmarks may be detected in the images to morph and align the images with the pose templates to obtain standard poses. The plurality of images may be combined and presented in two-dimensional and three-dimensional models with labels and the total surface area burn score.
Medical devices, and methods of use therewith, suitable for at least partial implantation within the gastrointestinal portions of a body and having at least one anti-gastric distress agent are provided. The anti-gastric distress agent can include antacids, H2 blockers, proton pump inhibitors, or any combination thereof. The medical device can also include one or more sections having one or more anti-gastric distress agent or antimicrobial agents. The medical device has a length such that when the device is at least partially implanted the first section is accessible to the gastrointestinal portion of the patient&#39;s body. A second section having an antimicrobial agent may be external to the gastrointestinal portion. Preferably, device includes a first and second anti-gastric distress agent each having a different controlled release rate. The therapeutic agents can be disposed on one or more surfaces of the medical device and/or impregnated with the material of the medical device.
1,187,830. Pharmaceutical composition comprising polynucleotides. MERCK &amp; CO. Inc. 15 Dec., 1967 [23 Dec., 1966; 25 May, 1967; 9 Aug., 1967; 22 Nov., 1967], No. 57079/67. Heading A5B. [Also in Division C3] A pharmaceutical composition for administration to persons and animals to induce in them the formation of interferon as a microbe-resisting substance, comprises a pharmaceutical carrier and a multistranded polynucleotide substantially free from proteins and other substances that inhibit the formation of interferon when the polynucleotide is administered to humans or animals or is added to a culture of living animal or human cells. The polynucleotide is suitably a polymer resulting from the complexing of two of the following homopolynucleotides:-polyadenylic acid, polyuridylic acid, polyinosinic acid, polycytidylic acid and cytidylcytidine; or is a ribonucleic acid that has been released by phenol from a ribonucleic acid complex elaborated by the growth of P. funiculosum; or the polynucleotide may be released from reovirus type 3 virions or the polynucleotide may be the isolated replicative intermediate form elaborated in living cells infected with a DNA or RNA virus.
This invention provides for the assessment of susceptibility to disease e.g. HIV-1 by assessment of an individual&#39;s FUT2 genotype or associated phenotype. The normal non-variant FUT2 allele codes for an α (1, 2) fucosyltransferase enzyme associated with a characteristic phenotype. Some people are homozygotes for a genetic variant of FUT2 which is characterised by an enzyme-inactivating nonsense change at position 143 of the amino acid sequence, so that a tryptophan codon is converted into a stop codon. Individuals homozygous for the variant form also have a characteristic phenotype. Homozygotes for the less common variant allele (se) are less likely to be susceptible to HIV-1 infection than an individual homozygous for the more common normal allele (SE). Heterozygotes (SE/se) are at most risk of HIV-1 infection in comparison to the other FUT2 genotypes (se/se, SE/SE).
Construction of a recombinant tissue plasminogen activator (namely r-tPA) recombinant plasmid and a prokaryotic supernatant expression and purification method of the recombinant tissue plasminogen activator relate to construction, prokaryotic expression and purification technologies of tissue plasminogen activator recombinant plasmid. On the basis of full-length gene plasmid containing human tPA, a 3C sequence which can remove tags on the vector is introduced into a N end, a RGDS sequence which raises targeting is introduced into a C end, and PQE30 is used as a vector to construct a PQE30-rt-PA recombinant plasmid. Then, expression is induced by an autoinduction method. After bacteria crushing by an ultrasonic method, a Ni&lt;2+&gt; affinity column is used for r-tPA protein purification. PreScission protease is used for digesting 3C oligopeptide on the fusion protein, so as to remove a His-Tag. Finally, a molecular sieve is used for further purification so as to obtain high-purity r-tPA protein. The r-tPA protein is used for preparation of a thrombolytic drug with thrombus dissolution specificity.
PURPOSE:A protecting agent for mucous membranes, obtained by dissolving sodium polyacrylate in a solvent consisting essentially of a water, and capable of protecting the mucous membranes, e.g. rectum, vagina, oral cavity, and nasal cavity, etc. CONSTITUTION:A protecting agent for mucous membranes obtained by dissolving sodium polyacrylate, preferably &gt;=10,000 viscosity-average polymerization degree (Pv) in water alone or a mixed solvent of water and a little another solvent, e.g. ethanol, ethylene glycol or glycerol, without irritating the skin. The above-mentioned solvent containing &lt;=50wt% preferably &gt;=5wt% liquid polyhydric alcohol, e.g. ethylene glycol, facilitates the dissolving action of the sodium polyacrylate, and the above-mentioned alcohol having the wetting property provides excellent protecting action on the mucous membranes due to the difficult drying property of the liquid. Another component, e.g. an emulsifying agent, germicide, hormonal agent or nutrient for the mucous membranes, etc. in a small amount may be added to the above-mentioned solution.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a bamboo- or bamboo grass-derived antimicrobial agent reduced in discoloration and/or scent while retaining its antimicrobial ability.  &lt;P&gt;SOLUTION: The antimicrobial composition comprises bamboo or bamboo grass or extract component(s) thereof, a clathrate compound and iodine. Specifically, the clathrate compound is a cyclodextrin. This antimicrobial composition is usable in filters, one form thereof being a mask. Further, this composition is variously usable in applications where antimicrobial, antiviral and antifungal properties are required to some extent.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a coenzyme Q10 preparation that is efficiently and orally absorbed even in a person having poor oral absorption of coenzyme Q10, readily taken even in an aged person and a sick person and has improved oral absorption.  &lt;P&gt;SOLUTION: The coenzyme Q10 oral preparation having improved absorption is prepared by dispersing coenzyme Q10 into a saturated fatty acid polyhydric alcohol ester solid at a normal temperature. Preferably the blending ratio is 0.1-100 parts wt. of coenzyme Q10 based on 100 parts wt. of the saturated fatty acid polyhydric alcohol ester. An 8-22C saturated fatty acid glycerol ester is preferably used as the saturated fatty acid polyhydric alcohol ester.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
This invention comprises the use of centrifugal force to introduce viable cells into a fibrous lattice, as well as fibrous lattices that are seeded with cells by the use of centrifugal force. A variety of fibrous lattices may be seeded by the methods of this invention, such as a highly porous lattice comprising collagen fibers crosslinked with glycosaminoglycan. Before the centrifugation, a piece of intact tissue is harvested from a donor site. It is treated with one or more substances, such as trypsin or collagenase, to dissociate cells from the tissue. The cells are then mixed with an aqueous solution to create an aqueous suspension of cells. A piece of fibrous lattice is placed within a container, referred to herein as a &#34;bucket&#34;, that is suitable for rotation by a centrifuge. The aqueous suspension of cells is placed within the bucket, in contact with the lattice. The centrifuge is then rotated. Centrifugal force causes the cells, which are denser than the aqueous solution, to be forced into the lattice in a relatively uniform distribution. By controlling various parameters, cells can be seeded into any desired location within a lattice
<b><br>Indroduction:</b> Significant dysphagia, aspiration pneumonia, and impossible oral nutrition in patients with unresectable or recurrent gastroesophageal malignancy or bronchial cancer invading the oesophagus with a tracheoesophageal fistula lead to cachexia. Dehiscence of the esophago-jejunal or gastroesophageal anastomosis may cause severe oesophageal haemorrhage. We believe that X-ray-guided oesophageal stent implantation (SEMS) is an alternative palliative method for microjejunostomy or full parenteral nutrition.</br> <b><br>Aim:</b> The aim of this paper was to assess the safety and efficacy of a novel X-ray-guided oesophageal stent implantation technique.</br> <b><br>Materials and methods:</b> This retrospective analysis included 54 patients (35 men and 19 women) treated for malignant dysphagia, gastroesophageal/gastrointestinal anastomotic fistula or bronchoesophageal fistula in two Surgical Units between 2010 and 2019, using a modified intravascular approach to oesophageal stent implantation.</br> <b><br>Results:</b> The presented modified intravascular method of oesophageal stent implantation was successfully performed in all described patients requiring oral nutrition restoration immediately following oesophageal stent implantation. Two patients with oesophageal anastomotic dehiscence died on postoperative days 7 and 9 due to circulatory and respiratory failure. One patient was reimplanted due to a recurrent fistula. Two patients with ruptured thoracic aneurysm and thoracic stent graft implantation due to oesophageal haemorrhage, who were implanted with an oesophageal stent, died on postoperative days 4 and 14.</br> <b><br>Conclusions:</b> The modified intravascular X-ray-guided SEMS technique may be a palliative treatment for patients with unresectable oesophageal malignancies.</br&gt.
NEW MATERIAL:The 3,5-disubstituted-triazolopyrimidine derivative of formula I (R is halogen, OH, lower alkoxy, phenoxy, substituted amino, or benzylthio). EXAMPLE:5-Chloro-3-phenyl-3H-1,2,3-triazolo[4,5-d]pyrimidine. USE:An antitumor agent. PROCESS:The compound of formula I (R is halogen) is prepared e.g. by catalytically reducing the compound of formula II in the presence of a Raney Ni catalyst, etc., and diazotizing and cyclizing the product with sodium nitrite or isoamyl nitrite, etc. The obtained compound can be converted to another compound of formula I (R is R&#39;) by reacting with the compound of formula R&#39;H (R is R other than halogen) in a solvent such as methanol.
Polyhydroxyalkanoates (PHAs) from which pyrogen has been removed are provided for use in numerous biomedical applications. PHAs which have been chemically modified to enhance physical and/or chemical properties, for targeting or to modify biodegradability or clearance by the reticuloendothelial system (RES), are described. Methods for depyrogenating PHA polymers prepared by bacterial fermentation processes are also provided, wherein pyrogens are removed from the polymers without adversely impacting the polymers&#39; inherent chemical structures and physical properties. PHAs with advantageous processing characteristics, including low melting points and/or solubility in non-toxic solvents, are also described. PHAs are provided which are suitable for use in in vivo applications such as in tissue coatings, stents, sutures, tubing, bone and other prostheses, bone or tissue cements, tissue regeneration devices, wound dressings, drug delivery, and for diagnostic and prophylactic uses. Properties which are selected for include degradability, elasticity, inclusion of functional groups or derivatized groups, which can in turn be used to attach targeting agents, and bioadhesion.